Business

Bearish Trend For ProShares UltraShort Stock: Neutral On B2Gold Corp Stock: Buy Luokung Technology Corp And Amarin Corporation plc Stocks

ProShares UltraShort (NYSEARCA: SDS) stock trades at $8.73

ProShares UltraShort (NYSEARCA: SDS) declined by 2.13% and settled at $8.73 on July 9, 2021. The stock pared 6.23% in the past 30 days. Its market cap is $184.61 million. 

B2Gold Corp (NYSEAMERICAN: BTG) Stock Zooms 2.51%

B2Gold Corp (NYSEAMERICAN: BTG) stock rose 2.51% and closed at $4.08 on July 9, 2021. The stock pared 3.32% in the past week. Its one-year high is $7.37. B2Gold stock expects to reverse the losing trend. However, investors are advised to wait to confirm the positive trend before taking any long positions in this stock. On June 24, 2021, B2Gold commenced arbitration proceedings against a West African nation – Mali, to deny the extension of the mining permit. The company invested $27 million in the last seven years in exploration. 

Luokung Technology Corp (NASDAQ: LKCO) stock increases 13.37%

Luokung Technology Corp (NASDAQ: LKCO) stock closed at $2.12 (up 13.37%) on July 9, 2021. It hit a low of $2.05 and a high of $2.18 during intraday trade on July 9, 2021. The stock pared 8.23% in the past week. Investors can add this stock to their portfolio for a target of $2.75, with a stop loss at $1.94. 

China-based company – Luokung entered a service contract with a top manufacturer to collect autonomous driving data and its management in the nation. eMapgo Technologies Co., Ltd’s subsidiary – Luokong, commenced implementing these services.  CEO of Luokung, Xuesong Song, said the company is indulged in establishing new service relationships with several global automobile manufacturers. It expects to gain from this relationship because the entire industry will add autonomous-vehicle capabilities.

Amarin Corporation plc (NASDAQ: AMRN) stock edges higher 4.14%

Amarin Corporation plc (NASDAQ: AMRN) stock gained 4.14% and closed at $4.53 on July 9, 2021. The stock pared 7.17% in the past month. A court of appeals in the US upheld the lower court’s ruling voiding Amarin patent. However, it received approval for Vazkepa from EMA and expects to commercialize the drug soon. 

Leave a Comment

Your email address will not be published.

*